625 related articles for article (PubMed ID: 25647234)
1. Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: implications for the treatment of multiple sclerosis.
Hammer LA; Zagon IS; McLaughlin PJ
Brain Res Bull; 2015 Mar; 112():42-51. PubMed ID: 25647234
[TBL] [Abstract][Full Text] [Related]
2. Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor.
Hammer LA; Zagon IS; McLaughlin PJ
Brain Res Bull; 2013 Sep; 98():122-31. PubMed ID: 23973432
[TBL] [Abstract][Full Text] [Related]
3. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
[TBL] [Abstract][Full Text] [Related]
4. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res; 2012 Sep; 1472():138-48. PubMed ID: 22820301
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum [Met
Ludwig MD; Zagon IS; McLaughlin PJ
Brain Res Bull; 2017 Sep; 134():1-9. PubMed ID: 28647454
[TBL] [Abstract][Full Text] [Related]
6. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Rahn KA; McLaughlin PJ; Zagon IS
Brain Res; 2011 Mar; 1381():243-53. PubMed ID: 21256121
[TBL] [Abstract][Full Text] [Related]
7. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.
McLaughlin PJ; McHugh DP; Magister MJ; Zagon IS
BMC Immunol; 2015 Apr; 16():24. PubMed ID: 25906771
[TBL] [Abstract][Full Text] [Related]
8. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
[TBL] [Abstract][Full Text] [Related]
9. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
[TBL] [Abstract][Full Text] [Related]
10. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
[TBL] [Abstract][Full Text] [Related]
11. Timing of treatment with an endogenous opioid alters immune response and spinal cord pathology in female mice with experimental autoimmune encephalomyelitis.
Patel C; Zagon IS; Pearce-Clawson M; McLaughlin PJ
J Neurosci Res; 2022 Feb; 100(2):551-563. PubMed ID: 34821408
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis.
Garay L; Gonzalez Deniselle MC; Sitruk-Ware R; Guennoun R; Schumacher M; De Nicola AF
J Neuroimmunol; 2014 Nov; 276(1-2):89-97. PubMed ID: 25200475
[TBL] [Abstract][Full Text] [Related]
13. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
14. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Berard JL; Wolak K; Fournier S; David S
Glia; 2010 Mar; 58(4):434-45. PubMed ID: 19780195
[TBL] [Abstract][Full Text] [Related]
15. Progesterone down-regulates spinal cord inflammatory mediators and increases myelination in experimental autoimmune encephalomyelitis.
Garay LI; González Deniselle MC; Brocca ME; Lima A; Roig P; De Nicola AF
Neuroscience; 2012 Dec; 226():40-50. PubMed ID: 23000619
[TBL] [Abstract][Full Text] [Related]
16. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
[TBL] [Abstract][Full Text] [Related]
17. Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis.
Bhasin M; Wu M; Tsirka SE
BMC Immunol; 2007 Jul; 8():10. PubMed ID: 17634104
[TBL] [Abstract][Full Text] [Related]
18. The role of CNS TLR2 activation in mediating innate versus adaptive neuroinflammation.
Luz A; Fainstein N; Einstein O; Ben-Hur T
Exp Neurol; 2015 Nov; 273():234-42. PubMed ID: 26342755
[TBL] [Abstract][Full Text] [Related]
19. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response.
Cassiani-Ingoni R; Muraro PA; Magnus T; Reichert-Scrivner S; Schmidt J; Huh J; Quandt JA; Bratincsak A; Shahar T; Eusebi F; Sherman LS; Mattson MP; Martin R; Rao MS
J Neuropathol Exp Neurol; 2007 Jul; 66(7):637-49. PubMed ID: 17620989
[TBL] [Abstract][Full Text] [Related]
20. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis.
Whitham RH; Bourdette DN; Hashim GA; Herndon RM; Ilg RC; Vandenbark AA; Offner H
J Immunol; 1991 Jan; 146(1):101-7. PubMed ID: 1701788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
